Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bay2416964
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
BAY2416964 is a potent, orally bioavailable small molecule antagonist of the aryl hydrocarbon receptor (AhR). It specifically binds to and inhibits AhR activation, thereby preventing AhR-mediated signaling. The drug is designed to counteract the immunosuppressive effects mediated by AhR ligands in the tumor microenvironment, restoring immune cell function and enhancing proinflammatory activity of antigen-presenting cells and T cells while reducing immunosuppressive myeloid cell activity. BAY2416964 is being developed primarily for the treatment of advanced solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), and other solid tumors. Preclinical studies have shown that it can restore immune responses against tumor cells and enhance cytotoxic T cell activity[1][2][3][7].
- Other names
- BAY 2416964BAY2416964BAY-2416964
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on bay2416964.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bay2416964.